9/21/2014 12:05 PM IPN.PA 39.81 € (+3.07 %) Data: Yahoo Finance
Startsidan

Press Releases

  • 9/1/2014

    Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe

    Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe
  • 8/29/2014

    Ipsen: 2014 half-year results and 2014 objectives

    Ipsen: 2014 half-year results and 2014 objectives
  • 8/27/2014

    Ipsen North America Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2014

    Ipsen North America Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2014
  • 7/17/2014

    New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors

    New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors
  • 7/11/2014

    Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe

    Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe
  • 7/1/2014

    Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

    Ipsen submits marketing authorization applications in the US and Europe for Somatuline®  (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
  • 6/4/2014

    Ordinary Shareholders’ Meeting of IPSEN S.A. held on 4 June 2014

    Ordinary Shareholders’ Meeting of IPSEN S.A.  held on 4 June 2014
  • 5/13/2014

    Ipsen announces a step forward in the resupply of Increlex® in the U.S.

    Ipsen announces a step forward in the resupply of Increlex® in the U.S.
  • 4/30/2014

    Ipsen’s first quarter 2014 sales

    Ipsen’s first quarter 2014 sales
  • 4/12/2014

    Ipsen announces a first set of results on positive phase III clinical study of Dysport® in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul

    Ipsen announces a first set of results on positive phase III clinical study of Dysport® in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul